Summary
Definition
History and exam
Key diagnostic factors
- presença de fatores de risco
- distensão abdominal
- fadiga
- sensibilidade nas mamas
- cefaleias
- humor depressivo, irritabilidade e tensão interna
- humor lábil
- efeito adverso sobre a vida
Other diagnostic factors
- aumento de apetite
- esquecimento e dificuldade de concentração
- outros sintomas subjetivos
- insônia ou hipersonia
- irritação gastrointestinal
- palpitações cardíacas
- fogacho
Risk factors
- mulheres na pré-menopausa e na pós-puberdade
- história familiar
- transtornos de humor
- tabagismo
- mulheres brancas
- abuso sexual e/ou trauma
- consumo de bebidas alcoólicas
Diagnostic tests
1st tests to order
- diário de sintomas prospectivos
Tests to consider
- testes da função tireoidiana
- níveis do hormônio folículo-estimulante
- rastreamento de depressão
- Hemograma completo
Treatment algorithm
SPM leve
SPM moderada a grave ou TDPM
Contributors
Authors
Nancy A. Phillips, MD
Associate Professor
Department of Obstetrics, Gynecology and Reproductive Sciences
Rutgers Robert Wood Johnson Medical School
New Brunswick
NJ
Disclosures
NAP has been reimbursed by Synexis Pharma, manufacturer of Ibrexafungerp, for attending advisory boards. NAP is on the North American Board of the North American chapter of the ISSVD (International Society for the Study of Vulvovaginal Disease). NAP has received grants from Syneos for a study on Myfembree.
Gloria Bachmann, MD
Professor
Department of Obstetrics, Gynecology and Reproductive Sciences
Rutgers Robert Wood Johnson Medical School
New Brunswick
NJ
Disclosures
GB declares that she has no competing interests.
Acknowledgements
Dr Nancy A. Phillips and Dr Gloria Bachmann would like to gratefully acknowledge Professor Margaret Rees and Dr Desiree Lie, the previous contributor to this topic.
Disclosures
MR and DL declare that they have no competing interests.
Peer reviewers
Julianne Toohey, MD
Obstetrician-Gynecologist
Department of Obstetrics and Gynecology
University of California Irvine Medical Center
Orange
CA
Disclosures
JT declares that she has no competing interests.
Carol Henshaw, MB ChB, MD
Consultant in Perinatal Mental Health
Liverpool Women's NHS Foundation Trust
Liverpool
UK
Disclosures
CH declares that she has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
American College of Obstetricians and Gynecologists. ACOG clinical practice guideline no. 7: management of premenstrual disorders. Dec 2023 [internet publication].Full text
Ismaili E, Walsh S, O'Brien PMS, et al; Consensus Group of the International Society for Premenstrual Disorders. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch Womens Ment Health. 2016 Dec;19(6):953-8. Abstract
Green LJ, O’Brien PMS, Panay N, et al; Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome: green-top guideline no. 48. BJOG. 2017 Feb;124(3):e73-105.Full text Abstract
World Health Organization. International classification of diseases 11th revision. Jan 2022 [internet publication].Full text
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Depression
- Doença tireoidiana
- Transtorno de ansiedade generalizada
More DifferentialsGuidelines
- Management of premenstrual disorders
- Management of premenstrual syndrome
More GuidelinesPatient information
Síndrome pré-menstrual
More Patient informationLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer